Search Results for agency_names:"National Institutes of Health"

The National Center for Advancing Translational Sciences is holding a closed meeting to discuss contract proposals for research on liver and brain organoids derived from human iPS cells. The meeting will occur virtually on April 17, 2025, from 12:00 p.m. to 5:00 p.m. It is closed to the public to protect confidential information and personal privacy. For any inquiries, Rahat (Rani) Khan, the Scientific Review Officer, can be contacted via email at rahat.khan@nih.gov or by phone at (301) 594-7319.

The National Institute on Aging has announced a closed meeting, set for April 9, 2025, from 1:00 p.m. to 4:00 p.m. This meeting will be conducted virtually and will focus on reviewing and evaluating grant applications related to clinical trials for aging conditions. The meeting is closed to the public to protect confidential information, such as trade secrets, patentable material, and personal data concerning individuals linked to the grant applications. For any inquiries, Dr. Maurizio Grimaldi serves as the contact person for this event.

The National Institute of Environmental Health Sciences announced upcoming closed meetings as per section 10(d) of the Federal Advisory Committee Act. These meetings will not be open to the public to protect confidential information and personal privacy. The meeting will take place virtually on February 19, 2021, and will involve a review of grant applications. Dr. Laura A. Thomas is the contact person for further information regarding the meeting.

The National Institutes of Health has announced a change in the previously scheduled meeting for the Oncology 2—Translational Clinical Integrated Review Group. The meeting will take place from May 1 to May 2, 2025, at their Rockledge Drive location in Bethesda, Maryland. This amendment updates the contact for the Scientific Review Officer, replacing Lawrence Ka-Yun Ng with Victor Panchenko, Ph.D. The meeting is closed to the public.

The National Institute of Nursing Research is holding a closed virtual meeting to review and evaluate small business grant applications. This meeting, set for April 17, 2025, will take place from 1:00 p.m. to 2:00 p.m. and will not be open to the public due to privacy concerns related to confidential information about grant applications. Joshua R. Wolff, Ph.D., is the contact person for the meeting, which falls under the Health and Human Services Department and the National Institutes of Health.

The National Institutes of Health (NIH) announced that a meeting of the National Center for Advancing Translational Sciences Special Emphasis Panel will take place on April 24, 2025. The meeting will be closed to the public to protect confidential information and personal privacy. During the meeting, the committee will review and evaluate contract proposals related to a benchtop device for batch evaporation. Dr. Rahat Khan will be the contact person for further inquiries.

The National Institutes of Health has announced upcoming closed meetings for committees associated with the National Institute of Neurological Disorders and Stroke. These meetings will review grant and cooperative agreement applications related to Neurological Disorders and Genome Editing Therapeutics. The discussions will remain private to protect sensitive personal and commercial information. Meetings will occur virtually on May 8-9 and May 12, 2025.

The National Institute of Neurological Disorders and Stroke will hold a meeting of the National Advisory Neurological Disorders and Stroke Council on May 14-15, 2025. The meeting will be open to the public on May 14 from 10:00 a.m. to 5:00 p.m., with discussions on administrative matters and program developments, and it will be available via videocast. The session on May 15, from 10:00 a.m. to 5:00 p.m., will be closed to the public to discuss confidential grant applications. Those wishing to attend or needing special accommodations should contact Dr. Andrea Meredith.

The National Cancer Institute is considering granting an exclusive patent license to Senti Bio for developing and commercializing certain therapies that target CD33-expressing cancers. These therapies involve using specially engineered immune cells, like T cells and NK cells, to recognize and attack cancer cells marked by the CD33 protein, commonly found in acute myeloid leukemia. People interested in this license must submit their comments or applications by January 29, 2021. The patent rights involved have been assigned to the U.S. government, and the license could apply worldwide.

The Center for Scientific Review announced several closed meetings to evaluate grant applications for scientific research. These meetings are scheduled to take place virtually at the National Institutes of Health on specific dates in February 2025 and will be restricted to the public to protect confidential information and personal privacy. Various committees focusing on fields such as cardiovascular science, bioengineering, oncology, biobehavioral processes, social psychology, and endocrinology will hold these sessions. Scientific Review Officers are designated for each committee to manage the proceedings and can be contacted for further information.